Randomized Trial Links Time of Day to Immunotherapy Success

Morning administration of checkpoint inhibitors significantly extended survival in patients with advanced non-small cell lung cancer, in the first randomized trial of immunotherapy timing. The results provide prospective support for aligning treatment with circadian biology as a simple way to improve cancer outcomes.